Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents.

Kaushik SB, Lebwohl MG.

J Am Acad Dermatol. 2018 Jul 11. pii: S0190-9622(18)32215-1. doi: 10.1016/j.jaad.2018.06.057. [Epub ahead of print] Review.

PMID:
30017705
2.

p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.

Škrlec K, Zadravec P, Hlavničková M, Kuchař M, Vaňková L, Petroková H, Křížová L, Černý J, Berlec A, Malý P.

Int J Mol Sci. 2018 Jul 1;19(7). pii: E1933. doi: 10.3390/ijms19071933.

3.

T300A variant of AT16L1 gene in a cohort of Algerian Crohn disease patients.

Aida I, Meddour Y, Kadiri H, Smara M, Bousseloub A, Kecili L, Gamar L, Belhocine K, Boussafsaf MA, Debzi N, Aouichat-Bouguerra S, Chaib S.

Curr Res Transl Med. 2018 Mar;66(1):9-14. doi: 10.1016/j.retram.2018.01.002. Epub 2018 Mar 5.

PMID:
29519712
4.

Genome-wide association studies in Crohn's disease: Past, present and future.

Verstockt B, Smith KG, Lee JC.

Clin Transl Immunology. 2018 Jan 31;7(1):e1001. doi: 10.1002/cti2.1001. eCollection 2018. Review.

5.

MicroRNA-425 facilitates pathogenic Th17 cell differentiation by targeting forkhead box O1 (Foxo1) and is associated with inflammatory bowel disease.

Yang X, He Q, Guo Z, Xiong F, Li Y, Pan Y, Gao C, Li L, He C.

Biochem Biophys Res Commun. 2018 Feb 5;496(2):352-358. doi: 10.1016/j.bbrc.2018.01.055. Epub 2018 Jan 10.

PMID:
29331376
6.

Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease.

Yamada M, Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Matsui S, Watanabe T, Nishida N, Kashida H, Kudo M.

Oncology. 2017;93 Suppl 1:20-26. doi: 10.1159/000481225. Epub 2017 Dec 20.

7.

Fecal bacteria from treatment-naive Crohn's disease patients can skew helper T cell responses.

Ma F, Zhang Y, Xing J, Song X, Huang L, Weng H, Wu X, Walker E, Wang Z.

Exp Cell Res. 2017 Dec 1;361(1):135-140. doi: 10.1016/j.yexcr.2017.10.011. Epub 2017 Oct 12.

PMID:
29031634
8.

Immunomodulatory effects of M2000 (β-D-Mannuronic acid) on TNF-α, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease.

Mohammed HA, Saboor-Yaraghi AA, Vahedi H, Yekaninejad MS, Panahi G, Hemmasi G, Lakzaei M, Mirshafiey A.

Int Immunopharmacol. 2017 Oct;51:107-113. doi: 10.1016/j.intimp.2017.08.011. Epub 2017 Aug 17.

PMID:
28822915
9.

Circulating and Tissue-Resident CD4+ T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation.

Hegazy AN, West NR, Stubbington MJT, Wendt E, Suijker KIM, Datsi A, This S, Danne C, Campion S, Duncan SH, Owens BMJ, Uhlig HH, McMichael A; Oxford IBD Cohort Investigators, Bergthaler A, Teichmann SA, Keshav S, Powrie F.

Gastroenterology. 2017 Nov;153(5):1320-1337.e16. doi: 10.1053/j.gastro.2017.07.047. Epub 2017 Aug 4.

10.

Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease.

Magro DO, Kotze PG, Martinez CAR, Camargo MG, Guadagnini D, Calixto AR, Vasques ACJ, Ayrizono MLS, Geloneze B, Pareja JC, Saad MJ, Coy CSR.

Intest Res. 2017 Jul;15(3):352-357. doi: 10.5217/ir.2017.15.3.352. Epub 2017 Jun 12.

11.

Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients.

Li J, Doty AL, Tang Y, Berrie D, Iqbal A, Tan SA, Clare-Salzler MJ, Wallet SM, Glover SC.

Clin Exp Immunol. 2017 Oct;190(1):143-153. doi: 10.1111/cei.12996. Epub 2017 Jul 7.

PMID:
28586085
12.

Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn's Disease and Ulcerative Colitis.

Li J, Ueno A, Iacucci M, Fort Gasia M, Jijon HB, Panaccione R, Kaplan GG, Beck PL, Luider J, Barkema HW, Qian J, Gui X, Ghosh S.

Dig Dis Sci. 2017 Sep;62(9):2357-2368. doi: 10.1007/s10620-017-4596-9. Epub 2017 Jun 1.

PMID:
28573508
13.

A role for interleukin 17A in IBD-related neuroplasticity.

Cervi AL, Moynes DM, Chisholm SP, Nasser Y, Vanner SJ, Lomax AE.

Neurogastroenterol Motil. 2017 Nov;29(11). doi: 10.1111/nmo.13112. Epub 2017 May 30.

PMID:
28560787
14.

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.

Hohenberger M, Cardwell LA, Oussedik E, Feldman SR.

J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31. Review.

PMID:
28521565
15.

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

Esfahani K, Miller WH Jr.

N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047. No abstract available.

16.

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.

Katsanos KH, Papadakis KA.

Gut Liver. 2017 Jul 15;11(4):455-463. doi: 10.5009/gnl16308. Review.

17.

Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity.

Saeed MA, Ng GZ, Däbritz J, Wagner J, Judd L, Han JX, Dhar P, Kirkwood CD, Sutton P.

Inflamm Bowel Dis. 2017 Apr;23(4):593-602. doi: 10.1097/MIB.0000000000001045.

PMID:
28296821
18.

Expression of CD200R1 and its Ligand CD200 on T-helper Lymphocytes of Pediatric Patients with Ulcerative Colitis and Crohn's Disease.

Elshal MF, Aldahlawi AM, Saadah OI, Mccoy JP.

Clin Lab. 2016 Aug 1;62(8):1521-1529. doi: 10.7754/Clin.Lab.2016.151231.

19.

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.

Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P, Baldassano RN, Hyams JS, Baker SS, Kellermayer R, Noe JD, Griffiths AM, Rosh JR, Crandall WV, Heyman MB, Mack DR, Kappelman MD, Markowitz J, Moulton DE, Leleiko NS, Walters TD, Kugathasan S, Wilson KT, Hogan SP, Denson LA.

Gastroenterology. 2017 May;152(6):1345-1357.e7. doi: 10.1053/j.gastro.2017.01.016. Epub 2017 Jan 26.

20.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS.

J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. Erratum in: J Am Acad Dermatol. 2017 Aug;77(2):390-390.e1.

Supplemental Content

Loading ...
Support Center